Christoph Boss

Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist

Marc Iglarz, Christoph A. Binkert, Keith Morrison et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 320 citations

Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study

Phillip Scheinberg, C. O. Wu, Óscar Núñez et al. · Haematologica · 2009 · 158 citations · Full text

The Discovery of <i>N</i>-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-<i>N</i>′-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist

Martin H. Bolli, Christoph Boss, Christoph A. Binkert et al. · Journal of Medicinal Chemistry · 2012 · 146 citations · Full text

Hypertension, High Oral Efficacy, Compound 17 +18

Discovery and Characterization of ACT‐335827, an Orally Available, Brain Penetrant Orexin Receptor Type 1 Selective Antagonist

Michel A. Steiner, John Gatfield, Catherine Brisbare‐Roch et al. · ChemMedChem · 2013 · 94 citations

Neurotransmitter, Affective Neuroscience, Synaptic Signaling +19

Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia

Georg Aue, Ndegwa Njuguna, Xin Tian et al. · Haematologica · 2009 · 93 citations · Full text